Role of cytokines and treatment algorithms in retinopathy of prematurity.

ABSTRACT:

Purpose of review

Currently, severe retinopathy of prematurity (ROP) is diagnosed by clinical evaluation and not a laboratory test. Laser is still considered standard care. However, anti-vascular endothelial growth factor (VEGF) agents are being used and there are questions whether and/or if to use them, what dose or type of agent should be considered and what agent may be most beneficial in specific cases. Also unclear are the effects of laser or anti-VEGF on severe ROP, refractive outcomes or infant development. This article reviews recent studies related to these questions and other trials for severe ROP.

Recent findings

Imaging studies identify biomarkers of risk (plus disease, stage 3 ROP, and ROP in zone I). Intravitreal bevacizumab or ranibizumab are reported effectiv

SUBMITTER: Hartnett ME 

PROVIDER: S-EPMC5495148 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature